OGN News and Press, Organon & Co. From 08/05/22

BofA Securities has downgraded Organon ( NYSE: OGN ) to neutral from buy following the company's recent Q2 2022 results as there are better opportunities for upside in pharma. The firm also lowered its price target to $37 from $40 (~14% upside based on Thursday's close...

Organon & Co. (OGN) Q2 2022 Earnings Conference Call August 4, 2022 08:30 ET Company Participants Jennifer Halchak - Vice President, Investor Relations Kevin Ali - Chief Executive Officer Matt Walsh - Chief Financial Officer Sandra Milligan - Head, R&...

The following slide deck was published by Organon & Co. in conjunction with their 2022 Q2 earnings call. For further details see: Organon & Co. 2022 Q2 - Results - Earnings Call Presentation

Despite reporting better than expected financials for 2Q 2022, Organon ( NYSE: OGN ), Merck’s ( MRK ) spinoff focused on women’s health and biosimilars, narrowed the range of 2022 revenue guidance, citing the ongoing unfavorable impact of forex rates. O...

Organon press release ( NYSE: OGN ): Q2 Non-GAAP EPS of $1.25 beats by $0.06 . Revenue of $1.59B (flat Y/Y) beats by $60M . Full year 2022 financial guidance ranges updated: Revenues range narrowed to $6.1 billion to $6.3 billion from a prior outlook o...

Second quarter 2022 revenues of $1,585 million Second quarter diluted earnings per share from continuing operations of $0.92 and non-GAAP adjusted diluted earnings per share from continuing operations of $1.25 Both reported and non-GAAP adjusted diluted earnings per share incl...

Organon ( NYSE: OGN ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is $1.19 (-30.8% Y/Y) and the consensus Revenue Estimate is $1.53B (-3.8% Y/Y). Over the last 1 year, OGN has beaten EPS est...

Viatris is down 40% since the spin-off. Financial metrics are positively increasing as one-time costs of the merger are decreasing. Safe and high dividend yield combined with exceptional free cash flow yield offer a great margin of safety. The restructuring of the company offers a...

Teva posted second-quarter results that exceeded market expectations. Teva's outlook looks bright. Opioid settlement another reason the stock added 30% after the earnings report. When Teva Pharmaceutical Industries Limited ( TEVA ) posted second-quarter results, the ...

Women’s healthcare company Organon ( NYSE: OGN ) and life science company Cirqle Biomedical announced a research collaboration and license agreement on Thursday to develop and commercialize an experimental contraceptive candidate. According to pre-clinical data, the...